You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuazepam
Accession NumberDB01589
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionQuazepam is a drug which is a benzodiazepine derivative. It induces impairment of motor function and has hypnotic properties. Quazepam is used to treat insomnia.
Structure
Thumb
Synonyms
Doral
Quazepamum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DoralTablet15 mg/1OralCutis Health, LLC2016-04-12Not applicableUs
QuazepamTablet15 mg/1OralA S Medication Solutions Llc2013-08-08Not applicableUs
QuazepamTablet15 mg/1Oralbryant ranch prepack2013-08-082016-10-13Us
QuazepamTablet15 mg/1OralThompson Medical Solutions Llc2016-04-12Not applicableUs
QuazepamTablet15 mg/1OralUnit Dose Services2013-08-08Not applicableUs
QuazepamTablet15 mg/1OralPreferred Pharmaceuticals, Inc.2013-08-152016-01-13Us
QuazepamTablet15 mg/1OralA S Medication Solutions Llc2013-08-08Not applicableUs
QuazepamTablet15 mg/1OralKLE 2, Inc.2013-08-082015-12-29Us
QuazepamTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-08-082016-01-13Us
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DoralNot Available
DormalinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJF8V0828ZI
CAS number36735-22-5
WeightAverage: 386.794
Monoisotopic: 386.026759579
Chemical FormulaC17H11ClF4N2S
InChI KeyIKMPWMZBZSAONZ-UHFFFAOYSA-N
InChI
InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
IUPAC Name
7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-1,4-benzodiazepine-2-thione
SMILES
FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2
Pharmacology
IndicationUsed to treat insomnia.
Structured Indications
PharmacodynamicsQuazepam is a benzodiazepine derivative. The main pharmacological action of quazepam is the enhancement of the neurotransmitter, GABA at the GABAA receptor.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionBioavailability is 29-35% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life39 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Quazepam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Quazepam is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Quazepam can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Quazepam is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Quazepam is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Quazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Quazepam.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Quazepam.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quazepam.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Quazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Quazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quazepam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Quazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Quazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Quazepam is combined with Amperozide.Experimental
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Quazepam.Approved
AprepitantThe serum concentration of Quazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.Approved, Investigational
ArmodafinilThe metabolism of Quazepam can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Quazepam.Approved
ArticaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Quazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Quazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Quazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Azaperone.Vet Approved
AzelastineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Quazepam is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Quazepam is combined with Baclofen.Approved
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Quazepam.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Quazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Quazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Quazepam.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Quazepam.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Quazepam.Approved
BexaroteneThe serum concentration of Quazepam can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Quazepam can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Quazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Quazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Quazepam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Quazepam.Approved, Illicit
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Quazepam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Quazepam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quazepam.Approved, Investigational
BuprenorphineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Quazepam.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Quazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Quazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Quazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Quazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quazepam.Approved, Illicit, Vet Approved
CapecitabineThe metabolism of Quazepam can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Quazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Quazepam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Quazepam.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Quazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Quazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Quazepam.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Quazepam can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Quazepam.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Quazepam.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Quazepam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Quazepam can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quazepam.Approved, Vet Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Quazepam.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Quazepam.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Quazepam can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Quazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Quazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Quazepam is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Quazepam.Approved, Illicit
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Quazepam.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonidine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Quazepam.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quazepam.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Quazepam.Approved, Illicit
ClotrimazoleThe metabolism of Quazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quazepam.Approved
CobicistatThe metabolism of Quazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Quazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quazepam.Approved, Illicit
ConivaptanThe serum concentration of Quazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Quazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Quazepam.Approved, Investigational
CyclosporineThe metabolism of Quazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Quazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Quazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Quazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Quazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Quazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Quazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Quazepam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Quazepam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Quazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Quazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Quazepam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quazepam.Approved, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Quazepam.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Quazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quazepam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Quazepam.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Quazepam.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Quazepam.Approved, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Quazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quazepam.Approved, Illicit
DihydroergotamineThe metabolism of Quazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quazepam.Experimental, Illicit
DiltiazemThe metabolism of Quazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Quazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Quazepam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quazepam.Approved, Illicit
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Quazepam.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Quazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Quazepam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Quazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Quazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
DronedaroneThe metabolism of Quazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Quazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Quazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quazepam.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Quazepam.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Quazepam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Quazepam.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Quazepam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Quazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Quazepam can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Quazepam.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Quazepam.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Quazepam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Quazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Quazepam can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quazepam.Approved, Illicit
EstroneThe serum concentration of Estrone can be increased when it is combined with Quazepam.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quazepam.Approved
EthanolQuazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Quazepam.Approved, Illicit
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Quazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Quazepam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Quazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Quazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Quazepam.Illicit, Vet Approved
EtravirineThe serum concentration of Quazepam can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Quazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Quazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Quazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Quazepam is combined with Flibanserin.Approved
FloxuridineThe metabolism of Quazepam can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Quazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Quazepam.Approved, Illicit
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Quazepam.Approved
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Quazepam.Approved, Illicit
FluorouracilThe metabolism of Quazepam can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Quazepam.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Quazepam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Quazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Quazepam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Quazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Quazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Quazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Quazepam can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Quazepam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Quazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quazepam.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Quazepam is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Quazepam.Approved, Illicit
GemfibrozilThe metabolism of Quazepam can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Quazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Quazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Quazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Quazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Quazepam.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Quazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Quazepam.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Quazepam.Approved
HydrocodoneQuazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved
IdelalisibThe serum concentration of Quazepam can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Quazepam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Quazepam can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quazepam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Quazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Quazepam can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Quazepam can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Quazepam.Approved, Investigational
IsavuconazoniumThe metabolism of Quazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe serum concentration of Isoflurane can be increased when it is combined with Quazepam.Approved, Vet Approved
IsoniazidThe metabolism of Quazepam can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Quazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Quazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Quazepam can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Quazepam.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Quazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Quazepam.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Quazepam.Approved
KetoconazoleThe metabolism of Quazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Quazepam is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Quazepam can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Quazepam.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Quazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Quazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quazepam.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Quazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quazepam.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Quazepam.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Quazepam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Quazepam is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Quazepam.Approved
LopinavirThe metabolism of Quazepam can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quazepam.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Quazepam.Approved
LosartanThe metabolism of Quazepam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Quazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quazepam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Quazepam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Quazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Quazepam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Vet Approved
MalathionThe serum concentration of Malathion can be increased when it is combined with Quazepam.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Quazepam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Quazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Melperone.Approved
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Quazepam.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quazepam.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Quazepam is combined with Metaxalone.Approved
MethadoneThe serum concentration of Methadone can be increased when it is combined with Quazepam.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Quazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Quazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Quazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Quazepam.Approved
MethotrimeprazineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Quazepam.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.Approved
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be increased when it is combined with Quazepam.Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Quazepam.Approved
MetyrosineQuazepam may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Quazepam.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Quazepam.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quazepam.Approved, Illicit
MifepristoneThe serum concentration of Quazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Quazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Investigational
MirtazapineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Quazepam can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Quazepam can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Quazepam can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Investigational
NafcillinThe serum concentration of Quazepam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quazepam.Approved
NefazodoneThe metabolism of Quazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Quazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Quazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Quazepam.Approved
NicardipineThe metabolism of Quazepam can be decreased when combined with Nicardipine.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Quazepam.Approved
NilotinibThe metabolism of Quazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Quazepam is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Quazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Quazepam.Approved, Investigational
OlaparibThe metabolism of Quazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Quazepam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Quazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Quazepam is combined with Opium.Approved, Illicit
OrphenadrineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Quazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Quazepam can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Quazepam.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Quazepam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Quazepam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quazepam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Quazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Quazepam.Approved
PantoprazoleThe metabolism of Quazepam can be decreased when combined with Pantoprazole.Approved
ParaldehydeQuazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Quazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Perazine.Investigational
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Quazepam.Approved
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Quazepam.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Quazepam is combined with Perospirone.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Quazepam.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Quazepam.Approved
PhenobarbitalThe metabolism of Quazepam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Quazepam is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Quazepam can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Quazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Quazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Quazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Quazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleQuazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Pramocaine.Approved
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Quazepam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Quazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quazepam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Quazepam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Quazepam.Approved
PrimidoneThe metabolism of Quazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Quazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Quazepam.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Quazepam.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quazepam.Approved, Vet Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Quazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Quazepam is combined with PSD502.Investigational
PyrimethamineThe metabolism of Quazepam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quazepam.Approved
QuinineThe metabolism of Quazepam can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Quazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Quazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Quazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quazepam.Approved
RifabutinThe metabolism of Quazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Quazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Quazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Quazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Quazepam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Quazepam.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Quazepam.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Romifidine.Vet Approved
RopiniroleQuazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Quazepam.Approved
RotigotineQuazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Quazepam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Quazepam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Quazepam is combined with Sage 547.Investigational
SaquinavirThe metabolism of Quazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Quazepam can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Quazepam.Approved, Investigational, Vet Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Quazepam.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Quazepam is combined with Sertindole.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Quazepam.Approved
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Quazepam.Approved, Vet Approved
SildenafilThe metabolism of Quazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Quazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Quazepam can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Quazepam.Approved, Investigational
St. John's WortThe serum concentration of Quazepam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Quazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.Approved, Investigational
SulfadiazineThe metabolism of Quazepam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Quazepam can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Quazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Quazepam.Approved
SuvorexantQuazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Quazepam.Approved
TandospironeThe risk or severity of adverse effects can be increased when Quazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Quazepam is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Quazepam can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Quazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Quazepam.Approved
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Quazepam.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrodotoxin.Investigational
ThalidomideQuazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Quazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quazepam.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiapride.Investigational
TicagrelorThe metabolism of Quazepam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Quazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Quazepam can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Quazepam can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Quazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Quazepam is combined with Topiramate.Approved
TramadolThe serum concentration of Tramadol can be increased when it is combined with Quazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quazepam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Quazepam.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Quazepam.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quazepam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quazepam.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Quazepam.Approved, Vet Approved
TrimethoprimThe metabolism of Quazepam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Quazepam is combined with Uc1010.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Quazepam.Approved, Investigational
ValsartanThe metabolism of Quazepam can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Quazepam can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Quazepam.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Quazepam is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Quazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Quazepam.Approved
XylazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Quazepam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Quazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Quazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zolazepam.Vet Approved
ZolpidemQuazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Quazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Quazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Quazepam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CD10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9385
Blood Brain Barrier+0.9789
Caco-2 permeable+0.5748
P-glycoprotein substrateSubstrate0.5341
P-glycoprotein inhibitor IInhibitor0.9324
P-glycoprotein inhibitor IIInhibitor0.8253
Renal organic cation transporterInhibitor0.6883
CYP450 2C9 substrateNon-substrate0.8255
CYP450 2D6 substrateNon-substrate0.8135
CYP450 3A4 substrateSubstrate0.5133
CYP450 1A2 substrateInhibitor0.7023
CYP450 2C9 inhibitorInhibitor0.5757
CYP450 2D6 inhibitorNon-inhibitor0.6337
CYP450 2C19 inhibitorInhibitor0.688
CYP450 3A4 inhibitorInhibitor0.7937
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9484
Ames testNon AMES toxic0.6683
CarcinogenicityNon-carcinogens0.7273
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9195 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.978
hERG inhibition (predictor II)Inhibitor0.6396
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7608616 No2008-06-032028-06-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point137.5-139 °CPhysProp
logP4.03SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00231 mg/mLALOGPS
logP4.76ALOGPS
logP5.06ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)18.93ChemAxon
pKa (Strongest Basic)2.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.6 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity93.47 m3·mol-1ChemAxon
Polarizability33.99 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-05aa-3988000000-ca1cf29da979ef46dd6cView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Thiolactam
  • Tertiary amine
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  4. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 09:30 / Updated on December 03, 2016 02:43